Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M

Open source

DOI: 10.1016/j.ejca.2023.04.016
Published: 2023 Aug
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2023.04.016,
  title = {Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.},
  author = {Kennedy OJ and Kicinski M and Valpione S and Gandini S and Suciu S and Blank CU and Long GV and Atkinson VG and Dalle S and Haydon AM and Meshcheryakov A and Khattak A and Carlino MS and Sandhu S and Larkin J and Puig S and Ascierto PA and Rutkowski P and Schadendorf D and Boers-Sonderen M and Di Giacomo AM and van den Eertwegh AJM and Grob JJ and Gutzmer R and Jamal R and van Akkooi ACJ and Robert C and Eggermont AMM and Lorigan P and Mandala M},
  year = {2023},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2023.04.016},
  url = {https://doi.org/10.1016/j.ejca.2023.04.016}
}

RIS

TY  - JOUR
TI  - Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
AU  - Kennedy OJ
AU  - Kicinski M
AU  - Valpione S
AU  - Gandini S
AU  - Suciu S
AU  - Blank CU
AU  - Long GV
AU  - Atkinson VG
AU  - Dalle S
AU  - Haydon AM
AU  - Meshcheryakov A
AU  - Khattak A
AU  - Carlino MS
AU  - Sandhu S
AU  - Larkin J
AU  - Puig S
AU  - Ascierto PA
AU  - Rutkowski P
AU  - Schadendorf D
AU  - Boers-Sonderen M
AU  - Di Giacomo AM
AU  - van den Eertwegh AJM
AU  - Grob JJ
AU  - Gutzmer R
AU  - Jamal R
AU  - van Akkooi ACJ
AU  - Robert C
AU  - Eggermont AMM
AU  - Lorigan P
AU  - Mandala M
PY  - 2023
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2023.04.016
UR  - https://doi.org/10.1016/j.ejca.2023.04.016
ER  -

APA

OJ, K., M, K., S, V., S, G., S, S., CU, B., GV, L., VG, A., S, D., AM, H., A, M., A, K., MS, C., S, S., J, L., S, P., PA, A., P, R., D, S., M, B., AM, D. G., AJM, V. D. E., JJ, G., R, G., R, J., ACJ, V. A., C, R., AMM, E., P, L., & M, M. (2023). Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2023.04.016

Source records

pubmed · retrieved 2026-09-26T19:04:22.747Z